We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intl.Brand | LSE:IBL | London | Ordinary Share | GB0031509804 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMEKF
EKF Diagnostics Holdings PLC
20 March 2020
EKF Diagnostics Holdings plc
("EKF", the "Company")
Investor results briefing update
As stated on the 4 March 2020, EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.
A briefing open to all investors was meant to take place on Tuesday 24 March 2020. The decision has been made by the management team to cancel this event. Instead the results presentation will be made available on the Company's website to download here: https://www.ekfdiagnostics.com/documents-reports.html
If you have any questions, please contact the team at Walbrook PR on 0207 933 8780 or at ekf@walbrookpr.com.
Hot Features
Premium
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman Tel: 029 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nomad & Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus/ Lianne Cawthorne Mob: 07980 541 893 / 07584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAKKCBDOBKDOND
(END) Dow Jones Newswires
March 20, 2020 03:00 ET (07:00 GMT)
1 Year International Brand Licensing Chart |
1 Month International Brand Licensing Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
